ArticleActa biochimica et biophysica Sinica2023

Developing drugs targeting CX3CL1 to treat heart diseases via immune/inflammatory mediation.

Lin Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.